Fingolimod: A potential first-in-class oral therapy for the treatment of relapsing-remitting multiple sclerosis

Formulary

Volumn 45, Issue 8, 2010, Pages 245-251

  Sobieraj, Diana M ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA1A INTERFERON; DILTIAZEM; FINGOLIMOD; GADOLINIUM; KETOCONAZOLE; PLACEBO; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMELANOTIC MELANOMA; AUTOIMMUNE DISEASE; BACKACHE; BASAL CELL CARCINOMA; BRADYCARDIA; CLINICAL TRIAL; CONTRAST ENHANCEMENT; COUGHING; DEGENERATIVE DISEASE; DIARRHEA; DISABILITY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; INFLUENZA; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NEVUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; RELAPSE; REMISSION; REPEATED DRUG DOSE; RETINA MACULA EDEMA; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE;

EID: 77958478038     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (28)

1. Neurological disorders: a public health approach. World Health Organization. Available at: http://www.who.int/mental-health/neurology/chapter- 3-a-neuro-disorders-public-h-chal-lenges.pdf. Accessed July 22, 2010.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372:1502-1517.
3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907-911.
4. Goodin DS, Frohman EM, Garmany GP Jr., et al. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-178.
5. FDA Advisory committee endorses f ngolimod for relapsing-remitting multiple sclerosis. Med-scape Medical News. Available at: http://www.medscape. com/viewarticle/723361. Accessed July 22, 2010.
6. Adachi K, Kohara T, Nakao N, et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett. 1995;5:853-856.
7. Brinkmann V, Cyster JG, Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004;4:1019-1025.
8. Chun J, Hartung HP. Mechanism of action of oral fngolimod (FTY720) in multiple sclerosis. Clin Neuropharm. 2010;33:91-101.
9. Billich A, Bornancin F, Devay P, Mechtcheriako-va D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphin-gosine kinases. J Biol Chem. 2003;278:47408-47415.
10. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodula-tory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007;323:469-476.
11. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit. 2004;26:585-587.
12. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Single-dose FTY720 pharmaco-kinetics, food effect, and pharmacological response in healthy subjects. Br J Clin Pharmacol. 2004;57:586-591.
13. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol. 2004;44:532-537. (Pubitemid 38509722)
14. Kovarik JM, Slade A, Voss B, et al. Ethnic sensitivity study of fngolimod in white and Asian subjects. Int J Clin Pharmacol Ther. 2007;45:98-109.
15. Kovarik JM, Schmouder RL, Serra D, et al. FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol. 2005;45:446-452.
16. Kovarik JM, Schmouder RL, Hartmann S, et al. Fingolimod ( FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J Clin Pharmacol. 2006;46:149-156.
17. FDA. Draft Clinical Pharmacology/Biophar-maceutics Review of Fingolimod. Available at: http://www.fda.gov/downloads/AdvisoryCom-mittees/ CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAd- visoryCommittee/UCM214672.pdf. Accessed July 22, 2010.
18. Kappos L, Antel J, Comi G, et al, for the FTY720 D2201 Study Group. Oral fngolimod ( FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124-1140.
19. O'Connor P, Comi G, Montalban X, et al, for the FTY720 D2201 Study Group. Oral fngo-limod ( FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009;72:73-79.
20. Comi G, O'Connor P, Montalban X, et al, for the FTY720 D2201 Study Group. Phase II study of oral fngolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 2010;16:197-207.
21. Kappos L, Radue EW, O'Connor PW, et al; on behalf of the FTY720 D2201 Study Group. Majority of patients with relapsing multiple sclerosis receiving oral f ngolimod (FTY720, a sphingosine-1-phosphate receptor modulator) remain free from any inflammatory activity: results of a 4-yr, phase II extension. J Neurol. 2009;256:S9.
22. Cohen JA, Barkhof F, Comi G, et al; for the TRANSFORMS Study Group. Oral fn-golimod or intramuscular interferon for re-lapsing multiple sclerosis. N Engl J Med. 2010;362:402-415.
23. Kappos L, Radue EW, O'Connor P, et al; for the FREEDOMS Study Group. A placebo-controlled trial of oral fngolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
24. Miller DH, Grossman RI, Reingold SC, McFar-land HF. The role of magnetic resonance techniques in understanding and managing multiple-sclerosis. Brain. 1998;121:3-24.
25. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002;360:1155-1162.
26. Kovarik JM, Dole K, Riviere GJ, et al. Keto-conazole increases f ngolimod blood levels in a drug interaction via CYP4F2. J Clin Pharmacol. 2009;49:212-218.
27. Kovarik JM, Lu M, Riviere GJ, et al. The effect on heart rate of combining single-dose fngolimod with steady-state atenolol or diltia-zem in healthy subjects. Eur J Clin Pharmacol. 2008;64:457-463.
28. FDA Panel gives green light to oral MS drug. Medpage Today. Available at: http://www. medpagetoday.com/ProductAlert/Prescrip-tions/20608. Accessed July 22, 2010.